Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Lee

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Inflammatory Bowel Diseases|September 19, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's DiseaseStefan Schreiber, Scott D Lee, C Janneke van der Woude, et al.
Inflammatory Bowel Diseases|July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 StudyScott D Lee, David T Rubin, William J Sandborn, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Crohn'S & Colitis 360|March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseaseQuazim A Alayo, Marc Fenster, Osama Altayar, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Inflammatory Bowel Diseases|August 24, 2021
Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II StudyGeert R D'Haens, Walter Reinisch, Scott D Lee, et al.
Inflammatory Bowel Diseases|September 19, 2025
Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's DiseaseStefan Schreiber, Scott D Lee, C Janneke van der Woude, et al.
Inflammatory Bowel Diseases|July 12, 2016
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 StudyScott D Lee, David T Rubin, William J Sandborn, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Crohn'S & Colitis 360|March 21, 2022
Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel DiseaseQuazim A Alayo, Marc Fenster, Osama Altayar, et al.
Gut|October 7, 2017
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA studyWilliam J Sandborn, Scott D Lee, Dino Tarabar, et al.
The New England Journal of Medicine|December 14, 2016
Ustekinumab as Induction and Maintenance Therapy for Crohn's DiseaseBrian G Feagan, William J Sandborn, Christopher Gasink, et al.
Pageof 5